acut
respiratori
infect
ari
frequent
infecti
diseas
human
great
major
respiratori
infect
observ
medic
practic
around
world
viral
etiolog
period
estim
children
age
year
die
everi
year
ari
respons
nearli
death
fatal
caus
bronchiti
pneumonia
associ
viral
infect
viral
respiratori
infect
also
associ
high
morbid
age
group
worldwid
exampl
hospit
children
brazil
belgium
itali
uk
attend
pediatr
servic
result
viral
respiratori
infect
current
follow
virus
shall
consid
caus
acut
respiratori
ill
children
human
respiratori
syncyti
viru
hrsv
parainfluenza
viru
type
influenza
viru
type
b
c
ia
ib
ic
adenovirus
adv
coronavirus
human
rhinoviru
hrv
subtyp
enteroviru
human
metapneumoviru
hmpv
human
bocaviru
hbov
wu
ki
polyomaviru
fig
howev
virus
present
high
rate
codetect
case
rhinoviru
enteroviru
human
coronaviru
bocaviru
polyomaviru
question
signific
etiolog
infect
season
respiratori
virus
describ
sever
studi
viral
infect
take
place
throughout
year
influenza
viru
predomin
winter
month
other
occur
chiefli
late
fall
winter
earli
spring
hpiv
hmpv
hcov
hrsv
adenovirus
found
worldwid
circul
sporad
endem
epidem
winter
spring
earli
summer
despit
great
number
viral
agent
involv
respiratori
infect
import
hrsv
lead
caus
acut
respiratori
infect
one
lead
caus
hospit
death
among
children
year
age
worldwid
year
respiratori
syncyti
viru
rsv
infect
lead
outpati
attend
hospit
children
less
year
age
us
addit
rsv
respons
hospit
death
among
adult
year
age
newborn
prematur
infant
chronic
lung
diseas
greater
risk
develop
sever
diseas
infect
hrsv
despit
import
vaccin
prophylaxi
hrsv
infect
effect
antivir
therapi
avail
current
latin
america
palivizumab
pz
synagi
medimmun
gaithersburg
md
usa
use
prophylaxi
therapi
infect
outbreak
respiratori
ill
character
cough
sneez
mucopurul
discharg
describ
coloni
chimpanze
walter
reed
armi
institut
research
wrair
washington
dc
usa
episod
rsv
isol
first
time
swab
throat
femal
chimpanze
call
chimpanze
coryza
agent
cca
viral
isol
perform
liver
cell
later
inocul
variou
laboratori
anim
mice
hamster
rabbit
rat
chimpanze
latter
one
develop
specif
symptom
one
attend
chimpanze
becam
sick
develop
symptom
similar
anim
although
attempt
isol
human
respiratori
syncyti
viru
unsuccess
increas
antibodi
titer
complement
fixat
cca
detect
parallel
seropreval
studi
conduct
human
gener
popul
reveal
presenc
antibodi
new
cca
agent
teenag
adult
follow
year
chanock
colleagu
isol
viru
similar
cca
child
pneumonia
anoth
croup
baltimor
agent
name
human
respiratori
syncyti
viru
hrsv
reflect
abil
form
syncytia
cell
cultur
tropism
human
respiratori
tract
serolog
studi
carri
time
indic
major
children
baltimor
infect
hrsv
year
age
similar
investig
divers
part
world
indic
hrsv
associ
diseas
lower
respiratori
tract
current
hrsv
recogn
viral
agent
frequent
relat
case
bronchiol
pneumonia
infanc
preschool
age
children
first
hrsv
infect
first
year
life
peak
incid
occur
first
month
approxim
children
develop
symptom
lower
respiratori
tract
involv
first
infect
although
reinfect
common
lifetim
clinic
symptom
older
children
adult
less
sever
group
patient
risk
develop
seriou
ill
result
lower
respiratori
tract
infect
hrsv
includ
children
younger
month
age
prematur
infant
immunodefici
children
children
chronic
lung
diseas
congenit
heart
diseas
also
studi
relat
hrsv
sever
infect
elderli
human
respiratori
syncyti
viru
hrsv
member
order
mononegaviral
mono
greek
mean
singl
simpl
nega
latin
mean
rna
neg
polar
viral
latin
mean
viru
classifi
within
pneumovirida
famili
genu
orthopneumoviru
member
orthopneumoviru
genu
bovin
respiratori
syncyti
viru
brsv
pneumonia
viru
mice
murin
pneumonia
viru
virion
pleomorph
diamet
nm
compos
intern
nucleocapsid
helic
symmetri
envelop
deriv
host
cytoplasm
membran
viral
glycoprotein
protrud
envelop
project
separ
interv
nm
involv
process
adher
penetr
viru
viral
genom
compos
singlestrand
rna
molecul
segment
neg
polar
infecti
particl
contain
one
function
copi
genom
fig
viru
contain
singlestrand
negativesens
rna
genom
nucleotid
nt
molecular
weight
da
serv
templat
transcript
messeng
rna
mrna
encod
protein
genom
transcript
take
place
direct
genom
rna
consist
region
nucleotid
presum
contain
viral
promot
first
nt
region
highli
suscept
inactiv
insert
delet
nucleotid
region
follow
gene
encod
protein
follow
order
n
p
sh
g
f
l
last
gene
l
follow
region
toler
insert
delet
nucleotid
first
nine
gene
separ
intergen
region
rang
nt
size
appar
import
role
modul
gene
express
show
littl
conserv
among
isol
begin
gene
contain
conserv
signal
gene
start
signal
compos
nine
nucleotid
except
l
gene
present
follow
differ
underlin
gene
end
semiconserv
sign
gene
end
signal
compos
nucleotid
whose
sequenc
drive
end
transcript
polyadenyl
last
two
gene
l
common
nt
consequ
gene
l
initi
transcript
insid
gene
two
orf
open
read
frame
give
rise
protein
organ
gene
hrsv
schemat
fig
cell
infect
hrsv
protein
identifi
nonstructur
protein
present
abund
cell
small
amount
virion
other
structur
protein
matrix
transcriptiol
elong
factor
protein
n
nucleoprotein
p
phosphoprotein
l
larg
polymeras
nucleocapsid
viral
protein
surfac
glycoprotein
g
attach
f
fusion
sh
small
hydrophob
glycoprotein
f
g
highli
access
neutral
antibodi
result
numer
chang
respons
host
immun
pressur
therefor
studi
molecular
weight
pm
kda
pm
kda
protein
respect
amino
acid
gene
encod
nucleotid
respect
function
well
understood
presum
relat
structur
regul
rna
synthesi
morphogenesi
virion
interact
host
cell
protein
p
l
n
associ
genom
rna
nucleocapsid
form
ribonucleoprotein
complex
consid
minimum
unit
necessari
transcript
replic
viru
p
protein
highli
phosphoryl
acid
key
role
regul
transcript
replic
process
amino
acid
molecular
weight
kda
gene
encod
nucleotid
nucleoprotein
n
amino
acid
molecular
weight
kda
gene
encod
nucleotid
main
structur
protein
nucleocapsid
close
associ
genom
rna
l
protein
consist
amino
acid
molecular
weight
kda
largest
viral
protein
gene
encod
l
protein
nucleotid
protein
pm
kda
pm
kda
intern
glycosyl
possess
respect
amino
acid
gene
encod
nucleotid
respect
protein
mediat
associ
nucleocapsid
viral
envelop
act
elong
transcript
sh
protein
small
molecul
amino
acid
pm
kda
insert
cytoplasm
membran
host
cell
via
hydrophob
sequenc
rang
amino
acid
function
protein
yet
clarifi
howev
integr
membran
assum
involv
adsorpt
penetr
denud
viru
glycoprotein
f
amino
acid
molecular
weight
kda
gene
encod
nucleotid
identifi
fusion
protein
respons
attach
viral
envelop
plasma
membran
host
cell
releas
nucleocapsid
directli
within
cytoplasm
also
respons
fusion
cell
infect
neighbor
cell
favor
format
syncytium
f
protein
synthes
inact
precursor
call
consist
two
domain
amino
acid
amino
acid
also
cleav
peptid
amino
acid
subunit
anchor
membran
subunit
rel
well
preserv
greatli
affect
function
delet
substitut
amino
acid
glycoprotein
g
type
ii
protein
anchor
membran
next
aminotermin
portion
hydrophob
domain
noncleav
signal
anchor
type
extend
residu
g
protein
amino
acid
length
depend
viral
strain
g
gene
compos
group
group
b
nucleotid
glycoprotein
g
viral
attach
engag
adsorpt
viru
shown
antibodi
g
glycoprotein
inhibit
bind
viru
cell
glycoprotein
g
special
interest
show
largest
variabl
viral
isol
support
larg
delet
multipl
amino
acid
substitut
without
loss
function
variabl
among
strain
hrsv
signatur
featur
alter
pathogen
adapt
viru
contribut
abil
viru
caus
repeat
infect
outbreak
escap
immun
system
glycoprotein
f
g
import
protein
involv
protect
immun
respons
antibodi
show
strong
neutral
activ
vitro
cell
receptor
specif
glycoprotein
g
first
identifi
krusat
streckert
show
preincub
viru
heparin
inhibit
infect
cell
cultur
g
protein
bind
heparin
result
suggest
heparin
glycosaminoglycan
gag
similar
heparin
present
cell
surfac
involv
bind
viru
cell
bind
site
glycoprotein
g
heparin
anoth
gag
map
amino
acid
protein
g
group
among
amino
acid
group
b
martinez
et
al
confirm
presenc
receptor
critic
bind
viru
viru
enter
cell
fusion
cell
membran
penetr
viral
envelop
remain
part
cell
membran
nucleocapsid
releas
cytoplasm
begin
process
transcript
viral
genom
viral
polymeras
gene
transcrib
sens
sign
promot
peak
synthesi
mrna
occur
h
infect
peak
protein
occur
h
addit
transcript
translat
protein
anoth
import
step
replic
viral
genom
produc
intermedi
posit
ssrna
serv
templat
gener
copi
viral
genom
ssrna
replic
process
take
place
cytoplasm
matur
viru
occur
first
instanc
combin
protein
n
p
genom
rna
subsequ
addit
auxiliari
protein
nucleocapsid
surfac
glycoprotein
insert
cytoplasm
membran
host
cell
next
step
matrix
protein
interact
noncoval
forc
cytoplasm
tail
surfac
glycoprotein
assembl
intern
structur
viru
interact
surfac
drive
bud
releas
viru
viru
acquir
lipoprotein
envelop
variabl
g
protein
concentr
extracellular
domain
two
variabl
region
high
content
serin
threonin
amino
acid
approxim
diverg
group
b
interspers
region
high
variabl
conserv
region
small
segment
amino
acid
four
cystein
residu
well
preserv
sampl
hrsv
suggest
region
respons
bind
viru
cell
receptor
howev
data
region
genotyp
emerg
current
lack
genotyp
hrsva
hrsvb
base
variabl
gprotein
gene
hrsv
genotyp
report
design
south
africa
recent
hrsvb
genotyp
describ
design
argentina
japan
korea
interestingli
strain
belong
genotyp
ba
hrsvb
exhibit
duplic
nucleotid
nt
second
variabl
region
protein
gene
g
associ
sever
clinic
manifest
brazil
genotyp
circul
current
hrsva
ba
genotyp
hrsvb
eshaghi
et
al
detect
group
one
repetit
nucleotid
gtcaagaggaaaccctccactcaaccacctccgaag
gctatctaagcccatcacaagtctatacaacatccg
ctermin
portion
gene
g
largest
duplic
describ
group
new
genotyp
call
found
hrsv
isol
genotyp
found
isol
brazil
genotyp
attain
natur
domin
becom
predomin
genotyp
circul
differ
area
world
area
specif
target
neutral
antibodi
type
chang
structur
lead
chang
immunogen
pathogen
viru
howev
addit
studi
still
requir
explor
pathogen
transmiss
replic
new
variant
sever
studi
molecular
epidemiolog
conduct
base
partial
sequenc
gene
g
sh
restrict
map
n
gene
enabl
reach
import
conclus
hrsv
circul
exist
sever
genotyp
circul
concurr
singl
outbreak
predomin
one
two
genotyp
tend
decreas
subsequ
outbreak
disappear
genotyp
hrsv
worldwid
distribut
strain
isol
distinct
commun
differ
year
may
relat
strain
isol
local
two
consecut
day
demonstr
pattern
tempor
necessarili
geograph
circul
within
strain
genotyp
occur
progress
buildup
amino
acid
chang
antigen
chang
detect
panel
antig
monoclon
antibodi
correl
posit
virus
phylogenet
tree
synonym
nucleotid
substitut
uniform
distribut
g
gene
nonsynonym
substitut
accumul
two
variabl
region
gene
g
howev
studi
minim
tempor
variat
gene
encod
g
protein
report
studi
perform
cuba
reveal
movement
extrem
homogen
sampl
outbreak
differ
five
nucleotid
compar
sampl
long
sinc
isol
signific
antigen
variat
hrsv
group
epidemiolog
yet
clear
antigen
dimorph
although
modest
rate
seem
contribut
high
incid
reinfect
first
year
life
howev
sever
reinfect
children
involv
virus
group
report
addit
indic
reinfect
heterolog
group
induc
seriou
clinic
sign
reinfect
homolog
sampl
two
group
b
circul
concurr
mani
epidem
year
divers
region
world
incid
vari
year
year
studi
conduct
el
salvador
santa
fe
bueno
air
argentina
reveal
presenc
group
outbreak
preval
group
local
rochest
boston
us
sapporo
japan
rio
de
janeiro
porto
alegr
preto
brazil
addit
cocircul
group
preval
group
b
may
switch
year
show
balanc
frequenc
group
differ
pathogen
two
group
clear
hall
et
al
imaz
et
al
verifi
increas
sever
children
infect
group
although
zelaya
et
al
found
greater
sever
children
infect
group
b
author
observ
signific
differ
pathogen
group
studi
carri
bogota
colombia
total
sampl
children
hospit
diagnosi
respiratori
infect
test
rsv
year
found
posit
averag
age
patient
analyz
studi
month
case
hrsv
infect
occur
period
march
may
wherea
bronchiol
case
diagnos
april
june
year
studi
chile
hrsv
detect
singl
pathogen
sampl
nasopharyng
aspir
patient
sampl
codetect
hrv
hospit
necessari
posit
case
hrsv
case
consid
seriou
case
coinfect
virus
hospit
coinfect
increas
sever
ill
brazil
mani
studi
alreadi
carri
investig
etiolog
acut
respiratori
diseas
period
nasopharyng
aspir
examin
children
less
year
old
hrsv
found
least
posit
respiratori
virus
identifi
children
hospit
acut
respiratori
diseas
countri
southern
latin
america
argentina
uruguay
outbreak
hrsv
occur
predominantli
winter
month
tropic
subtrop
climat
outbreak
alway
well
defin
although
ceara
locat
northeast
brazil
hrsv
caus
yearli
season
epidem
gener
februari
juli
moura
et
al
brazil
citi
rio
de
janeiro
paulo
hrsv
outbreak
start
autumn
rang
march
april
extend
winter
peak
incid
occur
usual
may
tabl
fortun
fatal
infect
hrsv
uncommon
estim
indic
number
death
around
year
children
year
age
howev
mortal
may
increas
significantli
children
present
background
predispos
seriou
diseas
congenit
heart
diseas
lung
diseas
prematur
infant
mortal
hrsv
infect
around
respect
high
mortal
rate
may
also
observ
individu
immunodefici
congenit
induc
chemotherapi
cancer
organ
transplant
especi
first
day
transplant
among
bone
marrow
transplant
recipi
mortal
becom
infect
hrsv
reach
studi
conduct
us
reveal
occurr
annual
hospit
elderli
pneumonia
associ
hrsv
cost
approxim
dollar
health
system
caus
death
per
year
laboratori
diagnosi
hrsv
carri
direct
detect
virus
viral
antigen
viral
genom
indirectli
base
detect
specif
antibodi
routin
clinic
laboratori
diagnosi
use
respiratori
secret
biolog
sampl
procedur
may
includ
viral
isol
cell
cultur
antigen
detect
immunofluoresc
enzymelink
immunosorb
assay
viral
rna
detect
revers
transcriptas
rt
polymeras
chain
reaction
pcr
best
sampl
obtain
aspir
wash
nasopharyng
secret
viral
particl
present
secret
highli
labil
sampl
kept
refriger
transport
laboratori
process
inocul
cell
cultur
isol
cell
cultur
regard
gold
standard
carri
wide
varieti
human
anim
cell
line
hela
cell
use
perini
et
al
cytopath
effect
usual
appear
within
day
inocul
character
presenc
larg
syncytia
result
cell
fusion
fig
nevertheless
viral
isol
cell
cultur
difficult
diagnosi
infect
often
accomplish
detect
hrsv
antigen
nasopharyng
epitheli
cell
immunofluoresc
fig
enzymelink
immunosorb
assay
faster
method
requir
presenc
infecti
viral
particl
last
two
method
requir
adequ
prepar
specimen
remov
excess
mucu
final
success
immunofluoresc
techniqu
asid
welltrain
personnel
wellprepar
sampl
requir
minimum
number
infect
cell
enabl
correct
diagnosi
hugh
et
al
compar
three
diagnost
techniqu
hrsv
isol
cell
cultur
direct
indirect
immunofluoresc
ifa
enzymelink
immunosorb
assay
elisa
immunofluorescencebas
method
detect
posit
sampl
show
higher
sensit
viral
isol
howev
sampl
found
posit
viral
isol
neg
immunofluoresc
demonstr
need
use
least
two
diagnost
method
rtpcr
techniqu
use
diagnosi
type
sampl
group
b
consid
highli
sensit
techniqu
especi
use
diagnosi
infect
sampl
amount
viral
load
sampl
small
case
sampl
taken
elderli
past
decad
molecular
method
consid
gold
standard
specif
abil
simultan
detect
differ
virus
advanc
real
timertpcr
quantit
q
rtpcr
specif
sensit
detect
hrsv
clinic
sampl
becam
suitabl
diagnosi
clinic
laboratori
rapid
antigen
detect
test
radt
dipstickbas
immunoassay
allow
rapid
qualit
detect
rsv
antigen
viral
fusion
protein
directli
nasopharyng
swab
nasopharyng
aspir
nasalnasopharyng
wash
specimen
symptomat
pediatr
patient
radt
provid
result
min
compar
approxim
min
convent
ifa
test
h
elisa
rapid
test
may
also
use
pointofcar
assay
method
although
effect
may
present
sever
drawback
includ
price
skill
personnel
issu
pose
challeng
hospit
pediatr
clinic
appli
best
medic
manag
monitor
treatment
children
suspect
infect
serolog
diagnos
made
neutral
assay
complement
fixat
determin
classspecif
immunoglobulin
igg
igm
elisa
immunofluoresc
techniqu
diagnosi
base
increas
antibodi
titer
acut
convalesc
titer
perform
serum
saliva
serolog
offer
limit
valu
diagnosi
primari
infect
children
less
month
age
case
present
increas
antibodi
titer
howev
infant
adult
serolog
regard
good
indic
reinfect
serolog
therefor
appropri
method
diagnosi
infect
hrsv
howev
great
import
clinic
epidemiolog
studi
ribavirin
nucleosid
analogu
guanosin
licens
sinc
treatment
choic
rsv
use
indic
form
aerosol
treatment
seriou
diseas
caus
hrsv
although
sever
studi
demonstr
effect
ribavirin
inhibit
replic
viru
improv
clinic
condit
result
decreas
need
supplement
oxygen
mechan
ventil
children
lower
respiratori
tract
infect
chronic
lung
diseas
infect
immunocompromis
individu
late
controversi
benefit
use
sinc
sever
studi
appear
indic
use
ribavirin
minim
effect
diseas
outcom
caus
hrsv
show
evid
decreas
durat
hospit
need
support
therapi
addit
high
cost
extend
treatment
h
inhal
sever
drug
candid
studi
past
decad
includ
sever
inhibitor
target
differ
hrsv
protein
despit
effort
present
time
antivir
drug
approv
treatment
heylen
et
al
develop
rsv
vaccin
hamper
incid
enhanc
respiratori
diseas
erd
follow
vaccin
formalininactiv
rsv
sinc
failur
multipl
live
viru
vaccin
develop
well
vaccin
platform
includ
viruslik
particl
peptidebas
vaccin
protein
subunit
vaccin
plasmid
dnabas
vaccin
mani
vaccin
evalu
anim
studi
human
none
howev
shown
suffici
promis
move
toward
licensur
clear
better
understand
viru
host
factor
contribut
diseas
protect
immun
still
necessari
develop
safe
effect
rsv
vaccin
altern
approach
identifi
vaccinerelev
epitop
includ
identif
neutral
rsv
protein
epitop
protect
immun
respons
safe
gener
develop
modern
pre
postrsv
fusion
f
protein
subunit
one
obstacl
develop
rsv
vaccin
difficulti
induc
longterm
protect
immun
evidenc
repeat
infect
throughout
life
incomplet
protect
afford
recipi
immun
prophylaxi
addit
immunogen
approach
target
singl
neutral
epitop
map
site
region
may
gener
focus
immun
respons
rsv
f
gener
polyclon
respons
gener
site
abas
vaccin
character
poor
bind
intact
rsv
f
protein
modest
vitro
neutral
evid
protect
rsv
challeng
vivo
palivizumab
pz
synagi
medimmun
human
igg
monoclon
antibodi
neutral
hrsv
interact
hrsv
f
glycoprotein
pz
fdaapprov
prophylaxi
hrsv
infect
five
monthli
pz
inject
span
annual
hrsv
epidem
period
shown
reduc
hospit
among
highrisk
children
us
howev
quasispeci
natur
rna
virus
allow
rapid
emerg
escap
mutant
immun
pressur
increas
use
pz
highrisk
children
immunocompromis
patient
provid
opportun
pzresist
mutant
aris
persist
among
human
howev
littl
known
mutat
patient
use
pz
